QScreen AI Completes Platform That Identifies Probable Drug a Person Has Consumed in Real Time from a Camera Alone - Targets Correctional Facilities Facing Coroner Scrutiny over Withdrawal Deaths

Patent-protected QAI Platform identifies the probable drug class - alcohol, opioids, benzodiazepines, stimulants, or cannabis from physiological camera data and simultaneously administers CIWA-Ar, COWS, C-SSRS and 10 further validated clinical instruments in under seven minutes with no hardware and no IT project; former Director of Pentagon Joint Artificial Intelligence Center advancing commercial engagement across US correctional facilities and national defense installations; Canadian correctional health outreach underway Toronto, Ontario--(Newsfile Corp. - April 27, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP), an innovator fusing Quantum-AI technologies to transform health screening, today provides a commercialization update. The Company has completed development of its QAI physiological AI clinical platform and has commenced outreach to prospective facility partners across correctional health and national defense verticals in Canada and the United States.